Mineralys Therapeutics Raises $650M+ in Capital Blitz to Clear Path for Lorundrostat Launch
Mineralys raised cash via $150M stock sale, $500M loan, and $200M royalty buyout to fund drug ahead of FDA decision; stock fell.
/ 3 items
#MLYS↓
Mineralys Shares Fall After FDA Accepts NDA for Lorundrostat – Explore-OSA Misses Primary Endpoint but Delivers Strong BP Reduction
Mineralys receives FDA acceptance of NDA for lorundrostat for hypertension. PDUFA target date: December 22, 2026. Explore-OSA missed primary endpoint but demonstrated meaningful BP reduction.
Blood Pressure Breakthroughs: Why Mineralys Stock Skyrocketed!
Mineralys shares surged 86% after AstraZeneca announced positive Phase 3 results for its similar blood pressure drug, Baxdrostat. "The results seem slightly worse than Mineralys' Lorundrostat," according to Jefferies. This could lead to business deals for MLYS, which may be "best in class".